This study aimed to systematically explore the potential mechanism of action of Qingbai Powder (QBP) in treating chronic soft tissue injury (CSTI) based on network pharmacology. Active ingredients and their corresponding targets of the herbal components in QBP were screened by integrating the TCMSP database. CSTI-related targets were retrieved from the GeneCards disease database. A "compound-target" interaction network was constructed. Protein-protein interaction (PPI) network analysis, Gene Ontology (GO) functional enrichment analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were employed to elucidate the biological functions of the core targets and associated signaling pathways. Resultly, a total of 35 active constituents of QBP and 136 potential therapeutic targets for CSTI were identified. The core active compounds were quercetin, kaempferol, beta-sitosterol, and stigmasterol. The core targets included AKT1, IL6, TNF, TP53, IL1B, CASP3, EGFR, PTGS2, ESR1, and MMP9. Enrichment analysis revealed that the core pathways were primarily enriched in the TNF signaling pathway, IL-17 signaling pathway, and NF-κB signaling pathway. In conclusion, this study preliminarily reveals the network regulation mechanism by which Qingbai Powder treats CSTI through the synergistic effects of "multi-component, multi-target, multi-pathway," providing a theoretical basis for its further pharmacological research and clinical application.

Qiang Deng, Yu Zhang. Exploration on the Mechanism of Action of Qingbai Powder in the Treatment of Chronic Soft Tissue Injury Based on Network Pharmacology. International Journal of Frontiers in Medicine (2025), Vol. 7, Issue 4: 118-127. https://doi.org/10.25236/IJFM.2025.070415.

[1] Tu YK, On Tong G, Wu CH, et al. Soft-tissue injury in orthopaedic trauma. Injury. 2008;39 Suppl 4:3-17.

[2] Dai DD. Observation on the efficacy of different external application methods of traditional Chinese medicine in treating chronic soft tissue injury pain. China Modern Drug Application. 2020;14(24):236-237.

[3] Zhu WH, Tang DZ, Wu XQ. Research progress on external treatment of traditional Chinese medicine for soft tissue injury. The Journal of Traditional Chinese Orthopedics and Traumatology. 2021; 33(02): 66-68.

[4] Parvez MK, Rishi V. Herb-Drug Interactions and Hepatotoxicity. Curr Drug Metab. 2019;20(4):275-282.

[5] Cheng T, Huang JJ. Research progress on oral administration of traditional Chinese medicine for acute soft tissue injury. The Journal of Traditional Chinese Orthopedics and Traumatology. 2017; 29(01): 39-41.

[6] Dong J. Effect of Qingbai Powder on the expression of collagen type I and III in skeletal muscle of rats with chronic soft tissue injury. Journal of Traditional Chinese Medicine. 2012;53(05):424-426.

[7] Dong J. Effect of Qingbai Powder on the expression of myosin heavy chain IIb and collagen type I and III in skeletal muscle of rats with chronic soft tissue injury. Lishizhen Medicine and Materia Medica Research. 2012;23(03):673-674.

[8] Li L, Yang L, Yang L, et al. Network pharmacology: A bright guiding light on the way to explore the personalized precise medication of traditional Chinese medicine. Chin Med. 2023;18(1):146.

[9] Feng YL, Li H, Liu J, et al. Research progress on quercetin. China Journal of Chinese Materia Medica. 2021;46(20):5185-5193.

[10] Salehi Namini M, Mohandesnezhad S, Mohandesnezhad S, Mansouri V, Tayebi L, Beheshtizadeh N. Enhancing bone regeneration using kaempferol as an osteoprotective compound: signaling mechanisms, delivery strategies, and potential applications. J Biol Eng. 2025;19(1):74.

[11] Chen YK, Zeng A, Luo ZH, et al. Research progress on pharmacological effects of β-sitosterol. Journal of Guangdong Pharmaceutical University. 2021;37(1):148-153.

[12] Wang S, Sun Y, Li CM, et al. Research progress on stigmasterol. China Pharmaceuticals. 2019; 28(23): 96-98.

[13] Lu Y, Azad N, Wang L, et al. Phosphatidylinositol-3-kinase/akt regulates bleomycin-induced fibroblast proliferation and collagen production. Am J Respir Cell Mol Biol. 2010;42(4):432-441.

[14] Pfeifer R, Darwiche S, Kohut L, Billiar TR, Pape HC. Cumulative effects of bone and soft tissue injury on systemic inflammation: a pilot study. Clin Orthop Relat Res. 2013;471(9):2815-2821.

[15] Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation. Blood. 2019;133(6):511-520.

[16] Liu Dongping, Xu Yang. p53, oxidative stress, and aging.[J]. Antioxidants & redox signaling, 2011, 15(6):1669-1678.

[17] Jia ZY, Zhang SZ. Research progress on traditional Chinese medicine regulating tumor necrosis factor and its signaling pathway in the treatment of osteoarthritis. Chinese Journal of Experimental Traditional Medical Formulae. 2022;28(20):250-257.

[18] Shi PQ, Zhu S, Qian YC. Study on IL-17 signaling transduction and function. Chinese Journal of Cell Biology. 2011;33(4):345-357.